paclitaxel has been researched along with Barrett Epithelium in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, J; Corrie, P; di Pietro, M; Fitzgerald, RC; Januszewicz, W; Liu, H | 1 |
| Becker, K; Bekesch, M; Busch, R; Ewald, P; Feith, M; Höfler, H; Langer, R; Sarbia, M; Siewert, JR; Specht, K; Stein, HJ | 1 |
| Nguyen, DM; Schrump, DS | 1 |
| Becker, K; Busch, R; Ewald, P; Feith, M; Höfler, H; Langer, R; Sarbia, M; Siewert, JR; Specht, K; Stein, HJ | 1 |
| Chen, KT | 1 |
| D'Amico, TA; Harpole, DH | 1 |
2 review(s) available for paclitaxel and Barrett Epithelium
| Article | Year |
|---|---|
Novel molecular targeted therapy for esophageal cancer.
Topics: Adenocarcinoma; Animals; Apoptosis; Barrett Esophagus; Cell Transformation, Neoplastic; Clinical Trials as Topic; Depsipeptides; DNA Methylation; Drug Screening Assays, Antitumor; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Glycoproteins; Histone Deacetylase Inhibitors; Humans; Mitogen-Activated Protein Kinases; Paclitaxel; Protein Kinase C; Signal Transduction | 2005 |
Molecular biology of esophageal cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Barrett Esophagus; Biomarkers, Tumor; Carcinoma, Squamous Cell; DNA Damage; Esophageal Neoplasms; Genes, p53; Humans; Incidence; Mutation; Paclitaxel; Prognosis; Risk Factors | 2000 |
4 other study(ies) available for paclitaxel and Barrett Epithelium
| Article | Year |
|---|---|
A sinister black finding in the stomach.
Topics: Acrylonitrile; Aged; Aniline Compounds; Barrett Esophagus; Benzimidazoles; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Humans; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Melanoma; Mutation; Neoplasm Metastasis; Paclitaxel; Prognosis; Stomach; Tomography, X-Ray Computed; Tubulin Modulators; Uveal Neoplasms | 2019 |
Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Calmodulin-Binding Proteins; Cisplatin; Combined Modality Therapy; DNA-Binding Proteins; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Multidrug Resistance-Associated Proteins; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Time Factors; Treatment Outcome | 2005 |
[Prediction of response to neoadjuvant chemotherapy in Barrett's carcinoma by quantitative gene expression analysis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; DNA Primers; Esophageal Neoplasms; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Neoadjuvant Therapy; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Cytology of small-cell carcinoma arising in Barrett's esophagus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Carboplatin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cytodiagnosis; Esophageal Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy, Adjuvant; Tomography, X-Ray Computed; Treatment Outcome | 2000 |